What is the current Price Target for the TransCode Therapeutics Inc stock?

The average TransCode Therapeutics Inc target price is $10.20. This is -26.57% lower than the current stock price. The highest price target is -24.41%, the lowest is -27.29%. 3 Analysts have issued a price target TransCode Therapeutics Inc 2026 .

How high will the TransCode Therapeutics Inc stock rise?

No reliable answer can be given as to how high the TransCode Therapeutics Inc stock will rise. The performance of stocks, including the TransCode Therapeutics Inc stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the TransCode Therapeutics Inc stock today?

The performance of TransCode Therapeutics Inc stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the TransCode Therapeutics Inc stock fall?

The decline in TransCode Therapeutics Inc stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

TransCode Therapeutics Inc Forecast, price target & analysts

$12.25

11.81% today

Nasdaq, Jul 29, 06:13 pm CET

ISIN

US89357L1052

Symbol

RNAZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

TransCode Therapeutics Inc Target price 2025 - Analyst rating & recommendation

TransCode Therapeutics Inc Classifications & Recommendation:

Buy

86%

Hold

14%

TransCode Therapeutics Inc Price Target

Target Price	$10.20
Price	$13.89
Deviation	26.57% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target TransCode Therapeutics Inc 2026 . The average TransCode Therapeutics Inc target price is $10.20. This is 26.57% register free of charge lower than the current stock price. The highest price target is $10.50 24.41% register free of charge , the lowest is $10.10 27.29% register free of charge .
	A rating was issued by 7 analysts: 6 Analysts recommend TransCode Therapeutics Inc to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the TransCode Therapeutics Inc stock has an average upside potential 2026 of 26.57% register free of charge . Most analysts recommend the TransCode Therapeutics Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-1,319.62	-4.46
	98.65%	99.66%
P/E		negative

3 Analysts have issued a TransCode Therapeutics Inc forecast for earnings per share. The average TransCode Therapeutics Inc EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-1,319.62	98.65%
2025	$-4.46 99.66% Unlock
2026	$-0.33 92.60% Unlock
2027	$-0.24 27.27% Unlock

Current	-2.63	19.45%
2025	-2.63 18.51% Unlock
2026	-35.97 1,267.68% Unlock
2027	-47.96 33.33% Unlock

TransCode Therapeutics Inc...

Current TransCode Therapeutics Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
HC Wainwright & Co.	Locked ➜ Locked	Locked	Apr 16 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Mar 13 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 07 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 06 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Dec 18 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Nov 15 2024
HC Wainwright & Co.	Locked ➜ Locked	Locked	Oct 24 2024

Analyst Rating	Date
Locked HC Wainwright & Co.: Locked ➜ Locked	Apr 16 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Mar 13 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 07 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 06 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Dec 18 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Nov 15 2024
Locked HC Wainwright & Co.: Locked ➜ Locked	Oct 24 2024

Discover more stocks with a high price target

BioNTech SE - ADR 24.35%

Alibaba Group Holding Ltd 23.33%

Deutsche Telekom 22.23%

Pfizer 17.48%

Tencent Holdings Ltd. 17.44%

Rheinmetall 16.70%

Infineon 16.43%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now